Why the study?
Inflammation contributes to cell death in ischemic brain injury, and preclinical evidence suggests IL-1β worsens injury, prompting examination of the contribution of the NLRP3 inflammasome.
Does targeting the NLRP3 inflammasome reduce ischemic brain injury in a mouse stroke model?
Does targeting the NLRP3 inflammasome reduce ischemic brain injury in a mouse stroke model?
In a mouse model of stroke, targeting the NLRP3 inflammasome did not reduce ischemic brain injury, contradicting previous reports.
NLRP3-independent thrombotic stroke injury cautions against this target clinically; leaves open alternative inflammasome pathways in humans.
Background and Purpose- A major process contributing to cell death in the ischemic brain is inflammation. Inflammasomes are multimolecular protein complexes that drive inflammation through activation of proinflammatory cytokines, such as IL (interleukin)-1β. Preclinical evidence suggests that IL-1β contributes to a worsening of ischemic brain injury. Methods- Using a mouse middle cerebral artery thrombosis model, we examined the inflammatory response after stroke and the contribution of the NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome to ischemic injury. Results- There was a marked inflammatory response after stroke characterized by increased expression of proinflammatory cytokines and NLRP3 and by recruitment of leukocytes to the injured tissue. Targeting NLRP3 with the inhibitor MCC950, or using mice in which NLRP3 was knocked out, had no effect on the extent of injury caused by stroke. Conclusions- These data suggest that the NLRP3 pathway does not contribute to the inflammation exacerbating ischemic brain damage, contradicting several recent reports to the contrary.
No takes yet. Share an insight, caveat, or question.
Lemarchand et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: